A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients

Trial Details

NCT ID
NCT05908409
Phase
PHASE1 / PHASE2
Sponsor
IDP Discovery Pharma S.L.
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • IDP-121
Locations (sample)
  • Santander, Cantabria, Spain|43.46589,-3.80493
  • Salamanca, Castille and León, Spain|40.96882,-5.66388
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899
  • Madrid, Spain|40.4165,-3.70256

Key Eligibility Criteria

  • Age ≥18 years
  • Performance status (ECOG) ≤ 2
  • Life expectancy ≥3 months
  • Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →